Jessica(Sharma)AilaniMDFAHS FAAN

PubMed

• Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
  Paul Rizzoli, Michael J Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco, Stephanie J Nahas, Jessica Ailani, Rosa De Abreu Ferreira, Julia Ma, Jonathan H Smith, ...> ;The Journal of Headache and Pain. 2024 Mar 11
• Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
  Messoud Ashina, Jessica Ailani, Jan Versijpt, Simona Sacco, Dimos D Mitsikostas, Cecilie Laurberg Christoffersen, Bjørn Sperling, Anders Ettrup, Lipton, R.> ;European Journal of Neurology. 2024 Feb 1
• Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF tr...
  Jessica Ailani, Peter McAllister, Paul K Winner, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Bjørn Sperling, Anders Ettrup, Roger Cady> ;BMC Neurology. 2023 Sep 6
• Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
  E Anne MacGregor, Susan Hutchinson, Hongxin Lai, Brett Dabruzzo, Sung Yun Yu, Joel M Trugman, Jessica Ailani> ;Headache. 2023 Sep 1
• 4 citations
  Hemiplegic Migraine.
  Arathi Nandyala, Tulsi Shah, Jessica Ailani> ;Current Neurology and Neuroscience Reports. 2023 Jul 1
• 3 citations
  Temporomandibular Joint Disorder Comorbidities.
  Davis C Thomas, Junad Khan, Daniele Manfredini, Jessica Ailani> ;Dental Clinics of North America. 2023 Apr 1
• 3 citations
  Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data.
  David Kudrow, Rima Dafer, David W Dodick, Amaal Starling, Jessica Ailani, Carrie Dougherty, Kavita Kalidas, Feng Zhang, Rohini Jeswani, Nishil Patel, Ani C Khodavirdi> ;Headache. 2023 Mar 1
• 4 citations
  Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
  Bianca Raffaelli, Roberto De Icco, Michele Corrado, Maria Terhart, Jessica Ailani> ;Cephalalgia. 2023 Feb 1
• 4 citations
  Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
  Andrew M Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, Joel M Trugman, Brett Dabruzzo, Jessica Ailani, Lipton, R.> ;Headache. 2023 Mar 1
• 2 citations
  Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure.
  Stewart J Tepper, Jessica Ailani, Sutapa Ray, Joe Hirman, Stephen B Shrewsbury, Sheena K Aurora> ;The Journal of Headache and Pain. 2022 Nov 22
• 3 citations
  Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
  Kate Bedrin, Jessica Ailani, Carrie Dougherty> ;Headache. 2022 Nov 1
• 5 citations
  Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
  David W Dodick, Andrew M Blumenfeld, Rashmi B Halker Singh, Rachel Williams, Feng Zhang, Po-Wei Chen, Cheng-Pang Hsu, Cheng Peng, Josefin Snellman, Mahan Chehrenama, J...> ;Headache. 2023 Feb 1
• 13 citations
  Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review.
  Jessica Ailani, Eric A Kaiser, Paul G Mathew, Peter McAllister, Andrew F Russo, Christopher Vélez, Angela Pozo Ramajo, Ahmad Abdrabboh, Cen Xu, Soeren Rasmussen, Stewa...> ;Neurology. 2022 Nov 7
• 6 citations
  Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
  Jessica Ailani, Peter McAllister, Paul K Winner, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Bjørn Sperling, Anders Ettrup, Roger Cady> ;BMC Neurology. 2022 Jun 3
• 5 citations
  A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine.
  Arathi S Nandyala, Himanshu Suri, Carrie O Dougherty, Jessica Ailani> ;Clinical Neurology and Neurosurgery. 2022 Apr 1
• 1 citations
  Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations.
  Stewart J Tepper, Huma U Sheikh, Carrie O Dougherty, Stephanie J Nahas, Paul K Winner, Ananda Krishna Karanam, Andrew M Blumenfeld, Ahmad Abdrabboh, Soeren Rasmussen, ...> ;Headache. 2022 Apr 1
• 3 citations
  Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results fr...
  Stewart J Tepper, Jessica Ailani, Janet H Ford, Russell M Nichols, Lily Q Li, Phebe Kemmer, Austin L Hand, Antje Tockhorn-Heidenreich> ;Clinical Drug Investigation. 2022 Mar 1
• Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categor...
  Stewart J Tepper, Jessica Ailani, Janet H Ford, Russell M Nichols, Lily Q Li, Phebe Kemmer, Austin L Hand, Antje Tockhorn-Heidenreich> ;Clinical Drug Investigation. 2022 Mar 1
• 5 citations
  Patient preference for early onset of efficacy of preventive migraine treatments.
  Jessica Ailani, Paul Winner, Ann Hartry, Thomas Brevig, Martin Bøg, Anders Blaedel Lassen, Kevin Marsh, Katelyn Cutts, Agathe Le Lay> ;Headache. 2022 Mar 1
• 5 citations
  Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the ran...
  Peter McAllister, Paul K Winner, Jessica Ailani, Dawn C Buse, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Lahar Mehta, Anders Ettrup, Roger Cady, Lipton, R.> ;The Journal of Headache and Pain. 2022 Feb 7
• 7 citations
  Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
  Jessica Ailani, Dulanji K Kuruppu, Mallikarjuna Rettiganti, Tina Oakes, Krista Schroeder, Linda Wietecha, Martha Port, Andrew M Blumenfeld> ;Headache. 2022 Feb 1
• 10 citations
  Pharmacovigilance: reporting requirements throughout a product's lifecycle.
  Sylvia Lucas, Jessica Ailani, Timothy R Smith, Ahmad Abdrabboh, Fei Xue, Marco S Navetta> ;Therapeutic Advances in Drug Safety. 2022 Jan 1
• 28 citations
  The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
  Jessica Ailani, Matthew S Robbins, Burch, R.> ;Headache. 2022 Jan 1
• 12 citations
  Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
  Jessica Ailani, Andrew M Blumenfeld> ;Headache. 2022 Jan 1
• 21 citations
  Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data.
  David W. Dodick, Stewart J. Tepper, Jessica Ailani, Nicola Pannacciulli, Marco S. Navetta, Brett Loop, Feng Zhang, Ani C. Khodavirdi, Allison Mann, Ahmad Abdrabboh, Ja...> ;Headache. 2021 Sep 30
• Join now to see all